

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) A compound having the formula:



wherein

Ab is an antibody that binds to at least one antigen selected from the group consisting of RSV, IL-2 receptor, CEA, platelet IIb/IIIa receptor, EGF, HER-2 receptor, CD56, EGFR, CD33, CD22, and OBA1 antigens;

G is an intact glycosyl linking group covalently joining Ab to L;

L is a bond or a spacer moiety covalently joining G to T; and

T is a toxin,

wherein said spacer moiety is a member selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted aryl moieties.

2. (Canceled)

3. (Previously Presented) The compound according to claim 1, wherein said spacer moiety comprises a poly(ethylene glycol) moiety.

4. (Currently Amended) A compound having the formula:



wherein


Ab is an antibody that binds to at least one antigen selected from the group consisting of RSV, IL-2 receptor, CEA, platelet IIb/IIIa receptor, EGF, HER-2 receptor, CD56, EGFR, CD33, CD22, and OBA1 antigens;

G is an intact glycosyl linking group covalently joining Ab to L;

L is a spacer moiety covalently joining G to T; and

T is a toxin,

wherein L has the formula:



wherein

$L^1$  is a bond or a linker moiety covalently joining G to A;


A is an amplifier moiety; and

$L^2$  is a bond or a spacer moiety covalently adjoining A to T.

5. (Original) The compound according to claim 4, wherein said amplifier moiety is a polyamine moiety.

6. (Original) The compound according to claim 5, wherein said polyamine moiety is a dendrimer.

7. (Previously Presented) The compound according to claim 4, having the formula:




wherein

PEG is a straight- or branched-chain poly(ethylene glycol);

m is an integer from 1 to 6; and

n is an integer from 1 to 1,000.

8. (Previously Presented) The compound according to claim 4, having the formula:




wherein

m is an integer from 1 to 6; and

n is an integer from 1 to 1,000.

9. (Previously Presented) The compound according to claim 4, having the formula:




wherein

m is an integer from 1 to 6; and

n is an integer from 1 to 1,000.

10. (Currently Amended) A compound having the formula:



wherein

$\text{X}^1$ ,  $\text{X}^2$ ,  $\text{X}^3$ , and  $\text{X}^4$  are linking groups and are members selected from the group consisting of O, S, NH,  $(\text{CH}_2)_q\text{-NH}$ ,  $\text{NH-(CH}_2)_q$ ,  $\text{NH-C(O)-O}$ ,  $\text{O-C(O)-NH}$ ,  $(\text{CH}_2)_q\text{-NH-C(O)-O}$ ,  $\text{O-C(O)-NH-(CH}_2)_q$ ,  $\text{C(O)-O}$ ,  $\text{O-C(O)}$ ,  $(\text{CH}_2)_q\text{-NH-C(O)}$ ,  $\text{C(O)-NH-(CH}_2)_q$ ,  $\text{NH-C(S)}$ , and  $\text{C(S)-NH}$ ;

~~and wherein~~

Ab is an antibody that binds to at least one antigen selected from the group consisting of RSV, IL-2 receptor, CEA, platelet IIb/IIIa receptor, EGF, HER-2 receptor, CD56, EGFR, CD33, CD22, and OBA1 antigens;

G is an intact glycosyl linking group covalently joining Ab to  $\text{X}^1$ ;

T is a toxin;

A is an amplifier moiety;

Z is a bond cleaved by a metabolic/physiological process;


n is an integer from 1 to 1,000;

a is an integer from 1 to 10;

b is an integer from 1 to 10; and


q is an integer from 0 to 20.

11. (Currently Amended) A compound having the formula:



wherein

at least one of  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ , is :



wherein

Ab is an antibody that binds to at least one antigen selected from the group consisting of RSV, IL-2 receptor, CEA, platelet IIb/IIIa receptor, EGF, HER-2 receptor, CD56, EGFR, CD33, CD22, and OBA1 antigens;

G is an intact glycosyl linking group covalently joining Ab to Z<sup>1</sup>;

T is a toxin;

r is an integer from 1 to 2,500;

A is an amplifier moiety;

Z<sup>1</sup> is selected from the group consisting of O, S, and NH;

Z<sup>2</sup> is selected from the group consisting of NH, and NH-(CH<sub>2</sub>)<sub>q</sub>;

and


X<sup>1</sup>, X<sup>2</sup> and X<sup>3</sup> are linking groups and are members selected from the group consisting of O, S, NH, (CH<sub>2</sub>)<sub>q</sub>-NH, NH-(CH<sub>2</sub>)<sub>q</sub>, NH-C(O)-O, O-C(O)-NH, (CH<sub>2</sub>)<sub>q</sub>-NH-C(O)-O, O-C(O)-NH-(CH<sub>2</sub>)<sub>q</sub>, C(O)-O, O-C(O), (CH<sub>2</sub>)<sub>q</sub>-NH-C(O), C(O)-NH-(CH<sub>2</sub>)<sub>q</sub>, NH-C(S), and C(S)-NH

wherein

n is an integer from 1 to 1,000; and

q is an integer from 0 to 20.

12. (Currently Amended) A compound having the formula:



wherein

X<sup>1</sup>, X<sup>2</sup> and X<sup>4</sup> are linking groups and are members selected from the group consisting of O, S, NH, (CH<sub>2</sub>)<sub>q</sub>-NH, NH-(CH<sub>2</sub>)<sub>q</sub>, NH-C(O)-O, O-C(O)-NH, (CH<sub>2</sub>)<sub>q</sub>-NH-C(O)-O, O-C(O)-NH-(CH<sub>2</sub>)<sub>q</sub>, C(O)-O, O-C(O), (CH<sub>2</sub>)<sub>q</sub>-NH-C(O), C(O)-NH-(CH<sub>2</sub>)<sub>q</sub>, NH-C(S), and C(S)-NH;

wherein

Ab is an antibody that binds to at least one antigen selected from the group consisting of RSV, IL-2 receptor, CEA, platelet IIb/IIIa receptor, EGF, HER-2 receptor, CD56, EGFR, CD33, CD22, and OBA1 antigens;

G is an intact glycosyl linking group covalently joining Ab to X<sup>1</sup>;


T is a toxin;

A is an amplifier moiety;

n is an integer from 1 to 1,000; and

q is an integer from 0 to 20.

13. (Previously Presented) The compound according to claim 12, having the formula:



wherein

n is an integer from 1 to 1,000.

14.-25. (Cancelled)